IL-10-armed anti-CD19 CAR-T cells Meta10-19

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, and armed with the anti-inflammatory cytokine interleukin-10 (IL-10), with potential immunostimulating and antineoplastic activities. Upon administration, IL-10-armed anti-CD19 CAR-T cells Meta10-19 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. IL-10 may stimulate the differentiation and expansion of tumor specific cytotoxic CD8+ T cells.